14.74 USD
0 (0%)
14.74 USD
0 (0%)
Taking everything into account, BLU scores 2 out of 10 in our fundamental rating. BLU was compared to 525 industry peers in the Biotechnology industry. The financial health of BLU is average, but there are quite some concerns on its profitability. BLU is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- BLU had negative earnings in the past year.
- In the past year BLU has reported a negative cash flow from operations.
1.2 Ratios
- BLU has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BLU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for BLU has been increased compared to 1 year ago.
- Compared to 1 year ago, BLU has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 103.35 indicates that BLU is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 103.35, BLU belongs to the best of the industry, outperforming 99.52% of the companies in the same industry.
- BLU has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of BLU (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 103.35 |
ROIC/WACCN/A
WACC7.86%
2.3 Liquidity
- A Current Ratio of 33.42 indicates that BLU has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 33.42, BLU belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
- A Quick Ratio of 33.42 indicates that BLU has no problem at all paying its short term obligations.
- BLU has a Quick ratio of 33.42. This is amongst the best in the industry. BLU outperforms 97.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 33.42 | ||
| Quick Ratio | 33.42 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 12.00% over the past year.
- BLU shows a decrease in Revenue. In the last year, the revenue decreased by -6.25%.
- BLU shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -34.23% yearly.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Sales Q2Q%-25%
3.2 Future
- Based on estimates for the next years, BLU will show a very strong growth in Earnings Per Share. The EPS will grow by 35.40% on average per year.
- BLU is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 654.86% yearly.
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- BLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as BLU's earnings are expected to decrease with -9.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
5. Dividend
5.1 Amount
- No dividends for BLU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BELLUS HEALTH INC / BLU FAQ
Can you provide the ChartMill fundamental rating for BELLUS HEALTH INC?
ChartMill assigns a fundamental rating of 4 / 10 to BLU.
What is the valuation status of BELLUS HEALTH INC (BLU) stock?
ChartMill assigns a valuation rating of 1 / 10 to BELLUS HEALTH INC (BLU). This can be considered as Overvalued.
Can you provide the profitability details for BELLUS HEALTH INC?
BELLUS HEALTH INC (BLU) has a profitability rating of 0 / 10.
How financially healthy is BELLUS HEALTH INC?
The financial health rating of BELLUS HEALTH INC (BLU) is 8 / 10.
What is the expected EPS growth for BELLUS HEALTH INC (BLU) stock?
The Earnings per Share (EPS) of BELLUS HEALTH INC (BLU) is expected to decline by -27.52% in the next year.